Author:
Matsudo Kyoto,Takada Kazuki,Kinoshita Fumihiko,Hashinokuchi Asato,Nagano Taichi,Akamine Takaki,Kohno Mikihiro,Takenaka Tomoyoshi,Shimokawa Mototsugu,Oda Yoshinao,Yoshizumi Tomoharu
Funder
Japan Society for the Promotion of Science
Reference24 articles.
1. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer;Hellmann;N Engl J Med,2019
2. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC;Herbst;N Engl J Med,2020
3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019
4. Immune-resistant mechanisms in cancer immunotherapy;Kawakami;Int J Clin Oncol,2020
5. Primary, adaptive, and acquired resistance to cancer immunotherapy;Sharma;Cell,2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献